Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366171475> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- W4366171475 endingPage "S110" @default.
- W4366171475 startingPage "S110" @default.
- W4366171475 abstract "Children with moderate-to-severe atopic dermatitis (AD) are at risk for lower bone mineral density (BMD) and alkaline phosphatase (ALP) levels compared with healthy children. Low BMD and ALP could contribute to a higher lifetime prevalence of fractures and osteoporosis. The objective of this analysis is to report the impact of dupilumab treatment on markers of bone mineralization in children aged 6–12 years with moderate-to-severe AD in comparison to reference intervals. The analysis was performed retrospectively on sera from participants in LIBERTY AD PEDS (NCT03345914) and LIBERTY AD PED-OLE (NCT02612454). Bone biomarkers including bone ALP (BALP), procollagen type 1 N-terminal propeptide (P1NP), C-terminal crosslinking telopeptide of beta-1 collagen (β-CTX), osteocalcin (OC), and insulin-like growth factor 1 (IGF-1) were analyzed at baseline, and at 8, 12, and 16 weeks; only BALP was measured at 52 weeks. BALP geometric mean (standard error) levels were significantly increased in dupilumab-treated patients compared with placebo after 16 weeks (77.7 [1.02] μg/L vs 65.0 [1.04] μg/L,P < 0.0001). In treated patients at Week 16, levels for OC, P1NP and β-CTX, trended from below to within reference intervals levels, and levels for IGF-1 trended upwards, away from the lower limit of the reference interval.4,5Over 52 weeks, dupilumab treatment led to significant increases in BALP in all treated children, reaching levels up to 83.8 μg/L, an improvement from levels near the lower limit of the reference intervals at baseline. Overall results suggest an increase in bone mineralization biomarkers in pediatric patients with moderate-to-severe AD following dupilumab treatment." @default.
- W4366171475 created "2023-04-19" @default.
- W4366171475 creator A5000881970 @default.
- W4366171475 creator A5006224928 @default.
- W4366171475 creator A5014808806 @default.
- W4366171475 creator A5019561970 @default.
- W4366171475 creator A5035276238 @default.
- W4366171475 creator A5052200518 @default.
- W4366171475 creator A5067860204 @default.
- W4366171475 creator A5079040130 @default.
- W4366171475 creator A5083904076 @default.
- W4366171475 date "2023-05-01" @default.
- W4366171475 modified "2023-09-26" @default.
- W4366171475 title "645 Dupilumab treatment in children with moderate-to-severe atopic dermatitis increases levels of bone mineralization biomarkers" @default.
- W4366171475 doi "https://doi.org/10.1016/j.jid.2023.03.652" @default.
- W4366171475 hasPublicationYear "2023" @default.
- W4366171475 type Work @default.
- W4366171475 citedByCount "0" @default.
- W4366171475 crossrefType "journal-article" @default.
- W4366171475 hasAuthorship W4366171475A5000881970 @default.
- W4366171475 hasAuthorship W4366171475A5006224928 @default.
- W4366171475 hasAuthorship W4366171475A5014808806 @default.
- W4366171475 hasAuthorship W4366171475A5019561970 @default.
- W4366171475 hasAuthorship W4366171475A5035276238 @default.
- W4366171475 hasAuthorship W4366171475A5052200518 @default.
- W4366171475 hasAuthorship W4366171475A5067860204 @default.
- W4366171475 hasAuthorship W4366171475A5079040130 @default.
- W4366171475 hasAuthorship W4366171475A5083904076 @default.
- W4366171475 hasBestOaLocation W43661714751 @default.
- W4366171475 hasConcept C125870589 @default.
- W4366171475 hasConcept C126322002 @default.
- W4366171475 hasConcept C131075544 @default.
- W4366171475 hasConcept C134018914 @default.
- W4366171475 hasConcept C142724271 @default.
- W4366171475 hasConcept C160160445 @default.
- W4366171475 hasConcept C170033053 @default.
- W4366171475 hasConcept C181199279 @default.
- W4366171475 hasConcept C203014093 @default.
- W4366171475 hasConcept C204787440 @default.
- W4366171475 hasConcept C27081682 @default.
- W4366171475 hasConcept C2776541429 @default.
- W4366171475 hasConcept C2776886416 @default.
- W4366171475 hasConcept C2778329239 @default.
- W4366171475 hasConcept C2779824493 @default.
- W4366171475 hasConcept C44249647 @default.
- W4366171475 hasConcept C55493867 @default.
- W4366171475 hasConcept C71924100 @default.
- W4366171475 hasConcept C86803240 @default.
- W4366171475 hasConcept C90924648 @default.
- W4366171475 hasConceptScore W4366171475C125870589 @default.
- W4366171475 hasConceptScore W4366171475C126322002 @default.
- W4366171475 hasConceptScore W4366171475C131075544 @default.
- W4366171475 hasConceptScore W4366171475C134018914 @default.
- W4366171475 hasConceptScore W4366171475C142724271 @default.
- W4366171475 hasConceptScore W4366171475C160160445 @default.
- W4366171475 hasConceptScore W4366171475C170033053 @default.
- W4366171475 hasConceptScore W4366171475C181199279 @default.
- W4366171475 hasConceptScore W4366171475C203014093 @default.
- W4366171475 hasConceptScore W4366171475C204787440 @default.
- W4366171475 hasConceptScore W4366171475C27081682 @default.
- W4366171475 hasConceptScore W4366171475C2776541429 @default.
- W4366171475 hasConceptScore W4366171475C2776886416 @default.
- W4366171475 hasConceptScore W4366171475C2778329239 @default.
- W4366171475 hasConceptScore W4366171475C2779824493 @default.
- W4366171475 hasConceptScore W4366171475C44249647 @default.
- W4366171475 hasConceptScore W4366171475C55493867 @default.
- W4366171475 hasConceptScore W4366171475C71924100 @default.
- W4366171475 hasConceptScore W4366171475C86803240 @default.
- W4366171475 hasConceptScore W4366171475C90924648 @default.
- W4366171475 hasIssue "5" @default.
- W4366171475 hasLocation W43661714751 @default.
- W4366171475 hasOpenAccess W4366171475 @default.
- W4366171475 hasPrimaryLocation W43661714751 @default.
- W4366171475 hasRelatedWork W2012733509 @default.
- W4366171475 hasRelatedWork W2020299418 @default.
- W4366171475 hasRelatedWork W2022695623 @default.
- W4366171475 hasRelatedWork W2024155257 @default.
- W4366171475 hasRelatedWork W2053638911 @default.
- W4366171475 hasRelatedWork W2067199708 @default.
- W4366171475 hasRelatedWork W2091140190 @default.
- W4366171475 hasRelatedWork W2128714854 @default.
- W4366171475 hasRelatedWork W2141577074 @default.
- W4366171475 hasRelatedWork W2155593667 @default.
- W4366171475 hasVolume "143" @default.
- W4366171475 isParatext "false" @default.
- W4366171475 isRetracted "false" @default.
- W4366171475 workType "article" @default.